The renoprotective effects of structured care in a clinical trial setting in type 2 diabetic patients with nephropathy | Zendy

WaiHang Leung | Zendy; WingYee So | Zendy; P. C. Y. Tong | Zendy; M. K. W. Lo | Zendy; K.-F. Lee | Zendy; G. T. C. Ko | Zendy; Juliana C.N. Chan | Zendy; Clive S. Cockram | Zendy; Barry M. Brenner | Zendy; S. Shahinfar | Zendy; Julia Critchley | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

The renoprotective effects of structured care in a clinical trial setting in type 2 diabetic patients with nephropathy

Author(s) -

WaiHang Leung,

WingYee So,

P. C. Y. Tong,

M. K. W. Lo,

K.-F. Lee,

G. T. C. Ko,

Juliana C.N. Chan,

Clive S. Cockram,

Barry M. Brenner,

S. Shahinfar,

Julia Critchley

Publication year - 2004

Publication title -

nephrology dialysis transplantation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.654

H-Index - 168

eISSN - 1460-2385

pISSN - 0931-0509

DOI - 10.1093/ndt/gfh408

Subject(s) - medicine , losartan , renal function , placebo , creatinine , diabetic nephropathy , nephropathy , diabetes mellitus , gastroenterology , urology , endocrinology , angiotensin ii , blood pressure , pathology , alternative medicine

The RENAAL Study has confirmed the renoprotective effects of Losartan in type 2 diabetes. In this subgroup analysis from the RENAAL Study, we hypothesized that the intensive care received by patients in a clinical trial setting also reduced the rate of decline in renal function through optimization of all risk factors.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research